These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9643008)

  • 21. Presenilin-1 is associated with Alzheimer's disease amyloid.
    Wisniewski T; Dowjat WK; Permanne B; Palha J; Kumar A; Gallo G; Frangione B
    Am J Pathol; 1997 Aug; 151(2):601-10. PubMed ID: 9250173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors.
    Gómez-Isla T; Growdon WB; McNamara MJ; Nochlin D; Bird TD; Arango JC; Lopera F; Kosik KS; Lantos PL; Cairns NJ; Hyman BT
    Brain; 1999 Sep; 122 ( Pt 9)():1709-19. PubMed ID: 10468510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain.
    Tamaoka A; Odaka A; Ishibashi Y; Usami M; Sahara N; Suzuki N; Nukina N; Mizusawa H; Shoji S; Kanazawa I
    J Biol Chem; 1994 Dec; 269(52):32721-4. PubMed ID: 7806491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
    Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
    Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.
    Vidal R; Calero M; Piccardo P; Farlow MR; Unverzagt FW; Méndez E; Jiménez-Huete A; Beavis R; Gallo G; Gomez-Tortosa E; Ghiso J; Hyman BT; Frangione B; Ghetti B
    Acta Neuropathol; 2000 Jul; 100(1):1-12. PubMed ID: 10912914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
    Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
    Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1-linked Alzheimer's disease.
    Mann DM; Pickering-Brown SM; Takeuchi A; Iwatsubo T;
    Am J Pathol; 2001 Jun; 158(6):2165-75. PubMed ID: 11395394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heparan sulfate proteoglycan expression in cerebrovascular amyloid beta deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains.
    van Horssen J; Otte-Höller I; David G; Maat-Schieman ML; van den Heuvel LP; Wesseling P; de Waal RM; Verbeek MM
    Acta Neuropathol; 2001 Dec; 102(6):604-14. PubMed ID: 11761721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.
    Li R; Lindholm K; Yang LB; Yue X; Citron M; Yan R; Beach T; Sue L; Sabbagh M; Cai H; Wong P; Price D; Shen Y
    Proc Natl Acad Sci U S A; 2004 Mar; 101(10):3632-7. PubMed ID: 14978286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble BACE-1 Activity and sAβPPβ Concentrations in Alzheimer's Disease and Age-Matched Healthy Control Cerebrospinal Fluid from the Alzheimer's Disease Neuroimaging Initiative-1 Baseline Cohort.
    Savage MJ; Holder DJ; Wu G; Kaplow J; Siuciak JA; Potter WZ;
    J Alzheimers Dis; 2015; 46(2):431-40. PubMed ID: 25790831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
    Ochalek A; Mihalik B; Avci HX; Chandrasekaran A; Téglási A; Bock I; Giudice ML; Táncos Z; Molnár K; László L; Nielsen JE; Holst B; Freude K; Hyttel P; Kobolák J; Dinnyés A
    Alzheimers Res Ther; 2017 Dec; 9(1):90. PubMed ID: 29191219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease.
    Blain JF; Bursavich MG; Freeman EA; Hrdlicka LA; Hodgdon HE; Chen T; Costa DE; Harrison BA; Kapadnis S; Murphy DA; Nolan S; Tu Z; Tang C; Burnett DA; Patzke H; Koenig G
    Alzheimers Res Ther; 2016 Aug; 8(1):34. PubMed ID: 27572246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.
    Davidson Y; Gibbons L; Pritchard A; Hardicre J; Wren J; Tian J; Shi J; Stopford C; Julien C; Thompson J; Payton A; Thaker U; Hayes AJ; Iwatsubo T; Pickering-Brown SM; Pendleton N; Horan MA; Burns A; Purandare N; Lendon CL; Neary D; Snowden JS; Mann DM
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):515-7. PubMed ID: 16543533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.
    Andreasen N; Hesse C; Davidsson P; Minthon L; Wallin A; Winblad B; Vanderstichele H; Vanmechelen E; Blennow K
    Arch Neurol; 1999 Jun; 56(6):673-80. PubMed ID: 10369305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
    Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ
    Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain.
    Pirttilä T; Mehta PD; Soininen H; Kim KS; Heinonen O; Paljärvi L; Kosunen O; Riekkinen P; Wisniewski HM
    Arch Neurol; 1996 Feb; 53(2):189-93. PubMed ID: 8639071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The beta amyloid protein precursor: mRNAs, membrane-associated forms, and soluble derivatives.
    Palmert MR; Podlisny MB; Golde TE; Cohen ML; Kovacs DM; Tanzi RE; Gusella JF; Whitehouse PJ; Witker DS; Oltersdorf T
    Prog Clin Biol Res; 1989; 317():971-84. PubMed ID: 2513588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.